Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 2/20 | 0.80 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | GLA | P06280 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | ATP4A | P20648 | 1/20 | 0.80 |
| ▸ | APEX1 | P27695 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | ATP4B | P51164 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.80 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605945 | 1.00 | HRH2 (0.80) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| SCHEMBL10858309 | 0.94 | HRH2 (0.71) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| SCHEMBL9867226 | 0.94 | HRH2 (0.70) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| SCHEMBL9867240 | 0.94 | HRH2 (0.77) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| SCHEMBL9867233 | 0.94 | HRH2 (0.70) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| SCHEMBL11169459 | 0.93 | HRH2 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| SCHEMBL11153611 | 0.93 | HRH2 (0.82) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| SCHEMBL11160799 | 0.93 | HRH2 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| SCHEMBL11169457 | 0.93 | HRH2 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| SCHEMBL11169465 | 0.93 | HRH2 (0.75) | HRH2SLC47A1MEN1SLC22A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | disclosed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | disclosed |
| US-8277782-B2 | Antiinflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins, inhibitor of activation of nuclear factor kappa beta | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-1294367-B1 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | PROCTER & GAMBLE (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20060193790-A1 | Promoting whole body health | THE PROCTER & GAMBLE COMPANY | 2006-08-31 | — | — | US | disclosed |
| EP-1294367-A2 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | The Procter & Gamble Company (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002096-A2 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| US-4105770-A | HISTAMINE ANTIAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193790-A1 | Promoting whole body health | IFNG, TNF, TLR6 | HRH2 602/4885SLC47A1 658/4885MEN1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.